nintedanib SSc-ILD
Selected indexed studies
- Should we use nintedanib as early therapy in patients with SSc-ILD? (Autoimmun Rev, 2024) [PMID:37844857]
- Current advances in the treatment of systemic sclerosis. (Curr Opin Pharmacol, 2022) [PMID:35447517]
- Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. (Am J Respir Crit Care Med, 2024) [PMID:37772985]
_Worker-drafted node — pending editorial review._
Connections
nintedanib SSc-ILD is a side effect of
Sources
- New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025. (2025) pubmed
- Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. (2021) pubmed
- Should we use nintedanib as early therapy in patients with SSc-ILD? (2024) pubmed
- Current advances in the treatment of systemic sclerosis. (2022) pubmed
- Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. (2024) pubmed
- Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). (2021) pubmed
- Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. (2023) pubmed
- Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results. (2024) pubmed
- Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. (2019) pubmed
- Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. (2021) pubmed